# OXLUMO
> **NDA214103** · New Drug Application · Sponsor: ALNYLAM PHARMS INC · Approved 2020-11-23
## Drug
- **FDA Application Number:** NDA214103
- **Application type:** New Drug Application
- **Brand name:** OXLUMO
- **Generic name:** LUMASIRAN
- **Active ingredients:** LUMASIRAN SODIUM
- **Dosage form:** SOLUTION
- **Route:** SUBCUTANEOUS
- **Marketing status:** Prescription
- **Sponsor:** ALNYLAM PHARMS INC
- **Manufacturer:** Alnylam Pharmaceuticals, Inc.
- **First approval:** 2020-11-23
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214103)
---
*AI Analytics · CC0 1.0*